Chardan Capital Cuts Zura Bio (NASDAQ:ZURA) Price Target to $10.00

Zura Bio (NASDAQ:ZURA) had its price target decreased by Chardan Capital from $12.00 to $10.00 in a report issued on Wednesday,Benzinga reports. Chardan Capital currently has a buy rating on the stock. Chardan Capital also issued estimates for Zura Bio’s FY2025 earnings at ($0.77) EPS and FY2026 earnings at ($0.78) EPS.

A number of other analysts have also issued reports on the company. HC Wainwright reissued a “neutral” rating and issued a $5.00 price target on shares of Zura Bio in a research note on Tuesday, December 24th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zura Bio in a report on Wednesday, December 11th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $15.00.

Zura Bio Price Performance

Shares of ZURA opened at $1.27 on Wednesday. Zura Bio has a 1 year low of $1.07 and a 1 year high of $6.35. The company’s 50 day simple moving average is $1.46 and its 200 day simple moving average is $2.73.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings results on Tuesday, March 25th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.09. The business had revenue of $0.00 million for the quarter. Sell-side analysts predict that Zura Bio will post -0.65 earnings per share for the current year.

Hedge Funds Weigh In On Zura Bio

A number of large investors have recently modified their holdings of the company. JPMorgan Chase & Co. increased its position in Zura Bio by 12,060.8% during the 4th quarter. JPMorgan Chase & Co. now owns 2,633,185 shares of the company’s stock worth $6,583,000 after purchasing an additional 2,611,532 shares in the last quarter. Braidwell LP purchased a new stake in Zura Bio during the third quarter worth approximately $10,040,000. Geode Capital Management LLC increased its position in shares of Zura Bio by 4.7% in the fourth quarter. Geode Capital Management LLC now owns 955,426 shares of the company’s stock worth $2,389,000 after acquiring an additional 42,801 shares in the last quarter. Sphera Funds Management LTD. purchased a new position in shares of Zura Bio in the 3rd quarter valued at $2,999,000. Finally, Millennium Management LLC lifted its holdings in shares of Zura Bio by 1,499.0% during the 4th quarter. Millennium Management LLC now owns 701,278 shares of the company’s stock valued at $1,753,000 after acquiring an additional 657,420 shares in the last quarter. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.